Neurobiologie psychedelik, drog a závislostí

Psychedelics are a class of neuroactive drug inducing psychedelic experiences with altered state of consciousness. In laboratory and under clinical settings, psychedelics are also unique tools to study human brain functions and the neurobiology of some psychopathological conditions, especially psychosis. Furthermore, recently psychedelics emerged to have ameliorative effects on depression, anxiety, addiction, and some other neuropsychiatric disorders.

The first aim is to study psychedelics in animal models, to elucidate the neurobiology of psychosis and depression, with focus on the neurochemistry, perception, sensorimotor and cognitive processing, neuroplasticity and brain activity and connectivity using electrophysiology and fMRI. The team is used to working with serotonergic psychedelics (tryptamines, phenylethylamines such as LSD, psilocybin, mescaline, DOB, 2C-B) as well as with NMDA antagonists, dissociative anesthetics such as ketamine, phencyclidine (PCP) and dizocilpine (MK-801) and cannabinoids. The emphasis is on experiments that have translational validity, and the extension of ongoing human experiments with psilocybin, ketamine, and cannabis.

The second aim is research on drug abuse, with a focus on new psychoactive substances (NPS). We compare and screen NPSs for their acute behavioral effects, pharmacokinetics, and metabolism, acute and chronic toxicity and addictive potential in animal models. Our expertise is on synthetic phenylethylamines (2C-B, DOB), cathinones (e.g., mephedrone, methylone, naphyrone, MDPV), aminoindanes (MDAI), the dissociative anesthetics (e.g., methoxetamine (MXE)), and selected synthetic cannabinoids. NPS effects are compared with known substances such as ecstasy, amphetamines, classic hallucinogens, dissociative anesthetics as well as natural cannabinoids (delta-9-THC).

We apply several behavioral approaches (e.g., open-field test, prepulse inhibition of the startle response, elevated plus maze, conditioned place preference etc.), electrophysiology, microdialysis, chromatography (LC-MS). Telemetry procedures are currently under development. Our team closely collaborates with the University of Chemical Technology in Prague (UCT), the Institute of Forensic Medicine and Toxicology at 1st Faculty of Medicine, Charles University in Prague (FMCU), the Pharmacology Institute at 3rd FMCU and the Prague Criminalistics Institute to perform a variety of analytical and toxicological studies and behavioral tests.

Klíčové publikace

1. Hložek T, Uttl L, Kadeřábek L, Balíková M, Lhotková E, Horsley RR, Nováková P, Šíchová K, Štefková K, Tylš F, Kuchař M, Páleníček T. Pharmacokinetic and behavioural profile of THC, CBD, and THC+CBD combination after pulmonary, oral, and subcutaneous administration in rats and confirmation of conversion in vivo of CBD to THC. Eur Neuropsychopharmacol. 2017 Dec;27(12):1223-1237. doi: 10.1016/j.euroneuro.2017.10.037. IF = 4.129.

2. Horsley RR, Lhotkova E, Hajkova K, Feriancikova B, Himl M, Kuchar M, Páleníček T. Behavioural, Pharmacokinetic, Metabolic, and Hyperthermic Profile of 3,4-Methylenedioxypyrovalerone (MDPV) in the Wistar Rat. Front Psychiatry. 2018 Apr 24;9:144. doi: 10.3389/fpsyt.2018.00144. IF = 2.857.

3. Tylš F, Páleníček T, Kadeřábek L, Lipski M, Kubešová A, Horáček J. Sex differences and serotonergic mechanisms in the behavioural effects of psilocin. Behav Pharmacol. 2016 Jun;27(4):309-20. doi: 10.1097/FBP.0000000000000198. IF = 2.218.

4. Páleníček, T., Fujáková, M., Brunovský, M., Horáček, J., Gorman, I., Balíková, M., Rambousek, L., Syslová, K., Kačer, P., Zach, P., Bubeníková-Valešová, V., Tylš, F., Kubešová, A., Puskarčíková, J., Höschl, C. Behavioral, neurochemical and pharmaco-EEG profiles of the psychedelic drug 4-bromo-2,5-dimethoxyphenethylamine (2C-B) in rats. Psychopharmacology. 2013, 225(1), 75-93. ISSN 0033-3158. DOI: 10.1007/s00213-012-2797-7. IF 3.988.

5. Pálenícek T, Hlinák Z, Bubeníková-Valesová V, Novák T, Horácek J. Sex differences in the effects of N,N-diethyllysergamide (LSD) on behavioural activity and prepulse inhibition. Prog Neuropsychopharmacol Biol Psychiatry. 2010 May 30;34(4):588-96. doi: 10.1016/j.pnpbp.2010.02.008. IF = 2.877.

 

 

Členové skupiny

Bochin, Marcel, Mgr.
Danda, Hynek, Mgr.
Griskova-Bulanova, Inga, Prof., PhD.
Grohmannová, Kateřina, Mgr.
Horsley, Rachel, Dr., BSc. (Hons), PG Cert, PhD, C Psychol, fHEA
Kuchař, Martin, Ing., Ph.D.
Leca, Nikola, Mgr. (Pinterová)
Lhotková, Eva, Ing.
Micale, Vincenzo, M.D. , Ph.D.
Olejníková, Lucie, Mgr., Ph.D.
Petrušková, Aneta, Mgr.
Syrová, Kateřina, Mgr.
Šíchová, Klára, Mgr., Ph.D.
Štefková, Kristýna, Mgr. et Mgr., Ph.D.
Vejmola, Čestmír, Mgr.
 


VP1 Experimentální neurobiologie VP2 Sociální psychiatrie VP3 Aplikované neurovědy a zobrazení mozku VP4 Epidemiologický a klinický výzkum závislostí VP5 Spánková medicína a chronobiologie VP6 Elektrofyziologie mozku VP7 Klinický výzkum duševních poruch VP8 Translační neurovědy Kancelář mezinárodní spolupráce AD Centrum Publikace Výzkumné projekty Evropské projekty Kontrahovaný výzkum Specifické výsledky výzkumu Etická komise Postgraduální studenti Semináře Ceny a ocenění Hledáme dobrovolníky
O NUDZ Výzkumné programy Léčebná péče Výuka Informační středisko Média Kontakty